Naturally Occurring Mutations of SARS-CoV‑2 Main Protease Confer Drug Resistance to Nirmatrelvir

Naturally Occurring Mutations of SARS-CoV‑2 Main Protease Confer Drug Resistance to Nirmatrelvir

Bibliographic Details
Main Authors:	Yanmei Hu, Eric M. Lewandowski, Haozhou Tan, Xiaoming Zhang, Ryan T. Morgan, Xiujun Zhang, Lian M. C. Jacobs, Shane G. Butler, Maura V. Gongora, John Choy, Xufang Deng, Yu Chen, Jun Wang
Format:	Article
Language:	English
Published:	American Chemical Society 2023-07-01
Series:	ACS Central Science
Online Access:	https://doi.org/10.1021/acscentsci.3c00538

Similar Items

A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations.
by: Jin Ou, et al.
Published: (2023-08-01)

Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir
by: Alessandro Paciaroni, et al.
Published: (2023-03-01)

Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
by: Andrea Citarella, et al.
Published: (2023-09-01)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
by: Karen Anbro Gammeltoft, et al.
Published: (2023-09-01)

Alkyne derivatives of SARS-CoV-2 main protease inhibitors including nirmatrelvir inhibit by reacting covalently with the nucleophilic cysteine
by: Brewitz, L, et al.
Published: (2023)

Autoprocessing and oxyanion loop reorganization upon GC373 and nirmatrelvir binding of monomeric SARS-CoV-2 main protease catalytic domain
by: Nashaat T. Nashed, et al.
Published: (2022-09-01)

Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
by: Chunlong Ma, et al.
Published: (2022-04-01)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023-05-01)

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistanceResearch in context
by: Jonathan Daniel Ip, et al.
Published: (2023-05-01)

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
by: Dirk Jochmans, et al.
Published: (2023-02-01)

Molecular docking and drug-likeness study of nirmatrelvir as promising drug candidates of dengue virus NS2B-NS3 protease
by: Huq, AKM Moyeenul, et al.
Published: (2023)

Molecular docking and drug-likeness study of nirmatrelvir as promising drug candidates of dengue virus NS2B-NS3 protease
by: Huq, A.K.M. Moyeenul, et al.
Published: (2023)

IFRS 16 «Rent»: the main causes of occurance
by: A. V. Kadochnikova
Published: (2022-09-01)

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
by: Paolucci Stefania, et al.
Published: (2012-10-01)

Managing nirmatrelvir/ritonavir (Paxlovid) interactions in general practice
by: Dagmara Mirowska-Guzel, et al.
Published: (2023-09-01)

Development of the Commercial Manufacturing Process for Nirmatrelvir in 17 Months
by: Christophe Allais, et al.
Published: (2023-03-01)

Total synthesis of antiviral drug, nirmatrelvir (PF-07321332)
by: Chandra Shekhar, et al.
Published: (2022-12-01)

Nirmatrelvir, a novel medication for COVID-19 treatment
by: Mohammad Reza Hajian, et al.
Published: (2023-01-01)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
by: Chaochao Qiu, et al.
Published: (2023-07-01)

Navigating the Evolution of Digital Twins Research through Keyword Co-Occurence Network Analysis
by: Wei Li, et al.
Published: (2024-02-01)

Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19
by: Hu CY, et al.
Published: (2023-12-01)

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
by: Sydney Paltra, et al.
Published: (2024-01-01)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
by: Yuan-Pin Hung, et al.
Published: (2022-02-01)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
by: Dimple Patel, et al.
Published: (2023-06-01)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022-11-01)

Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19
by: Junjun Chen, et al.
Published: (2024-04-01)

The main risks occurring while national payment system functioning
Published: (2020-01-01)

Naturally Occurring Mutations in HIV-1 Protease Gene Among People Living With HIV
by: Zahra Hasanshahi, et al.
Published: (2023-05-01)

Evaluation of nirmatrelvir + ritonavir therapy in patients with mild to moderate COVID-19
by: T.M. Levina, et al.
Published: (2024-03-01)

Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19?
by: article Editorial
Published: (2022-12-01)

Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis
by: Phylinda L. S. Chan, et al.
Published: (2023-12-01)

The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients
by: Xiang Z, et al.
Published: (2024-01-01)

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
by: Seyed Mohammad Reza Hashemian, et al.
Published: (2023-06-01)

Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?
by: Haein Kim, et al.
Published: (2022-10-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

Xanthohumol Is a Potent Pan-Inhibitor of Coronaviruses Targeting Main Protease
by: Yuxi Lin, et al.
Published: (2021-11-01)

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
by: Zhao X, et al.
Published: (2023-09-01)

Cotton flower metabolites inhibit SARS‐CoV‐2 main protease
by: Yufang Zhang, et al.
Published: (2022-10-01)

Case report: Rare epithelioid hemangioendothelioma occurs in both main bronchus and lung
by: Jiuyu Gong, et al.
Published: (2022-12-01)

Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease
by: János András Mótyán, et al.
Published: (2022-03-01)